feedback

Course Director

Fred Saad, MD, FRCS
Fred Saad, MD, FRCS

University of Montreal Hospital Center (CHUM)
University of Montreal
Montreal, Quebec, Canada

Faculty

Joe O'Sullivan
Joe O'Sullivan, MD, FRCPI, FFRRCSI, FRCR

Centre for Cancer Research and Cell Biology Queen's University Belfast
The Northern Ireland Cancer Centre
Belfast City Hospital
Belfast, Northern Ireland

Oliver Sartor
Oliver Sartor, MD

Tulane Cancer Center
Tulane University Medical School
Tulane Hospital
New Orleans, Louisiana, USA

Accredited by

Oakstone Publishing, LLC

View Activity Materials

Activity Details

Credit Types:CME
Credit Amount:0.75 Credits
Release Date:2017-Aug-15
Expiration Date:2018-Aug-14
Estimated Time for Completion:45 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, experts in prostate cancer discuss the practical implications of currently available data for advanced prostate cancer, especially as they relate to maximising patient outcomes through the use of evidence-based sequencing strategies and biomarkers. The faculty also discuss the potential for predictive biomarkers in clinical practice.

Upon completion of this activity, participants should be better able to:

  • Describe the recent clinical data that may impact the development of a long-term treatment plan for patients with advanced prostate cancer
  • Identify how targeted treatment approaches and use of biomarkers may affect real-world outcomes for patients with advanced prostate cancer
  • Apply evidence-based treatment strategies that allow for personalised prostate cancer management

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologists, nuclear medicine specialists, radiation oncologists, and other clinicians involved in prostate cancer management.

Faculty Disclosure Statement / Conflict of Interest Policy

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Course Director and Moderator

Fred Saad, MD, FRCS
Professor and Chairman of Urology
Director of GU Oncology
U of M Endowed Chair in Prostate Cancer
University of Montreal Hospital Center (CHUM)
University of Montreal
Montreal, Quebec, Canada

Fred Saad, MD, FRCS, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc; Astellas Pharma EMEA; Bayer AG; Janssen-Cilag Pharmaceuticals SA; and sanofi-aventis U.S. LLC.
Grant/Research Support from Amgen Inc; Astellas Pharma EMEA; Bayer AG; Janssen-Cilag Pharmaceuticals SA; and sanofi-aventis U.S. LLC.
Honoraria from Amgen Inc; Astellas Pharma EMEA; Bayer AG; Janssen-Cilag Pharmaceuticals SA; and sanofi-aventis U.S. LLC.
Advisory Board for Amgen Inc; Astellas Pharma EMEA; Bayer AG; Janssen-Cilag Pharmaceuticals SA; and sanofi-aventis U.S. LLC.

Faculty

Joe O'Sullivan, MD, FRCPI, FFRRCSI, FRCR
Professor of Radiation Oncology
Centre for Cancer Research and Cell Biology Queen's University Belfast
Consultant Clinical Oncologist and Clinical Lead for Radiotherapy
The Northern Ireland Cancer Centre
Belfast City Hospital
Belfast, Northern Ireland

Joe O'Sullivan, MD, FRCPI, FFRRCSI, FRCR, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer AG; Janssen-Cilag Pharmaceuticals SA; and sanofi-aventis U.S. LLC.
Grant/Research Support from Bayer AG.
Speakers Bureau participant with Bayer AG; Janssen-Cilag Pharmaceuticals SA; and sanofi-aventis U.S. LLC.
Advisory Board for Bayer AG; Janssen-Cilag Pharmaceuticals SA; and sanofi-aventis U.S. LLC.

Oliver Sartor, MD
C. E. & Bernadine Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana, USA

Oliver Sartor, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Algeta ASA; Amgen Inc; Bayer AG; Bellicum Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Ltd; Dendreon Pharmaceuticals LLC.; Exelixis; GlaxoSmithKline Plc; Johnson & Johnson Services, Inc.; Medivation Inc; OncoGenex Pharmaceuticals Inc.; and sanofi-aventis U.S. LLC.
Grant/Research Support from Algeta ASA; AstraZeneca Plc; Cougar Biotechnology Inc.; GlaxoSmithKline Plc; Johnson & Johnson Services, Inc.; and sanofi-aventis U.S. LLC.
Advisory Board for Algeta ASA; Amgen Inc; Bayer AG; Bellicum Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Ltd; Dendreon Pharmaceuticals LLC.; Exelixis; GlaxoSmithKline Plc; Johnson & Johnson Services, Inc.; Medivation Inc; OncoGenex Pharmaceuticals Inc.; and sanofi-aventis U.S. LLC.

PeerVoice Medical Director

Serena Welch has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabelled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labelled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabelled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and PeerVoice. Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

This CME activity is jointly provided by Oakstone Publishing, LLC and PeerVoice.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 70% is needed.

Media: Enduring Material
Release and Expiration Dates: August 15, 2017 - August 14, 2018
Time to Complete: 45 minutes

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerVoice or any of its supporters.


For technical assistance, please contact us.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.